User:Mr. Ibrahem/Esketamine

Esketamine, sold under the brand name Spravato among others, is a medication used for treatment-resistant depression or depression with acute thoughts of suicide. It; however, appears to be less effective than ketamine. It may also be used for anesthesia and pain. It is used as a nasal spray or by intravenous injection. In depression benefits generally occur within 24 hours.

Common side effects include dissociation, dizziness, sedation, headache, anxiety, vomiting, and increased blood pressure. Other side effects may include misuse. The compound is the S(+) enantiomer of ketamine. Use when breastfeeding is not recommended. It primarily acts by blocking N-methyl- D -aspartate (NMDA) receptors.

Esketamine came into medical use in Germany in 1997. It was approved for medical use in the United States and Europe in 2019. It is available as a generic medication. In the United States the nasal spray costs about 5,500 to 7,900 USD for the first month of treatment as of 2021. The intravenous formulation in the United Kingdom costs the NHS about £26 for 10 vials of 50 mg each.